Serco Group PLC (SEO) News

Form 4 - Statement of changes in beneficial ownership of securities

Revance Announces Pricing of $100.0 Million Public Offering of Common Stock

Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced the pricing of an underwritten public offering of...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Revance Announces Proposed Public Offering of Common Stock

Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced a proposed underwritten public offering of $100 million of...

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

– Q4 and full year 2023 product revenue (DAXXIFY® and RHA® Collection) of $58.5 million and $212.7 million, representing approximately 28% and...

Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024

Conference Call Scheduled for Wednesday, February 28, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (RVNC), today announced that the company...

Revance to Participate in Upcoming Investor Conferences

Revance Therapeutics, Inc. (RVNC) today announced that the company will be participating in the following investor conferences. Cowen 44th Annual...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 8-K - Current report

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities